NCT02361112已完成1 期
A Phase I Study of Pyrotinib In Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- The maximum-tolerated dose (MTD) will be defined as the maximum dose level at which no more than one subject out of three experiences has a dose-limiting toxicity (DLT) upon completing one treatment cycle.
研究概览
简要总结
Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib in combination with capecitabine in patients with HER2 positive metastatic breast cancer:
To evaluate the safety and tolerability of pyrotinib, and the maximum tolerated dose (MTD) To determine the dose-limiting toxicity (DLT) To determine the pharmacokinetic profile of Pyrotinib To assess preliminary antitumor activity To determine preliminary regimen dose for phase II study
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥18 and ≤70 years.
- •ECOG performance status of 0 to
- •Life expectancy of more than 12 weeks.
- •At least one measurable lesion exists.(RECIST 1.1)
- •Histologically or cytologic confirmed HER2 positive metastatic breast cancer which failed prior therapies.
- •No previous treatment of capecitabin during the past 1 year.
- •Required laboratory values including following parameters:
- •ANC: ≥ 1.5 x 109/L Platelet count: ≥ 100 x 109/L Hemoglobin: ≥ 9.0 g/dL Total bilirubin: ≤ 1.5 x upper limit of normal, ULN ALT and AST: ≤ 1.5 x ULN BUN and creatine clearance rate: ≥ 50 mL/min LVEF: ≥ 50% QTcF: < 470 ms
- •Signed informed consent.
排除标准
- •Subjects with third space fluid that can not be controled by drainage or other methods.
- •Steroid treatment for more than 50 days, or in need of long-term use of steroids.
- •Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption.
- •Less than 4 weeks from the last radiotherapy,chemotherapy，surgery，hermone treatment,target therapy, or less than 6 weeks from the nitrosoureas or mitomycin chemotherapy.
- •Subjects with no efficacy during the previous treatment of capecitabine.
- •Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry.
- •Subjects who can not interrupt the using of the drugs that may cause QT prolongation during study.
- •Subjects with intracranial lesions.
- •Subjects with bone or skin as the only target lesion
- •Treated or treating with HER2 tyrosine kinase inhibitors (TKIs) before study entry.
- •Receiving any other antitumor therapy.
- •Less than 4 weeks from the last clinical trial.
- •Known history of hypersensitivity to pyrotinib、capecitabine or any of its components or metabolites.
- •Ongoing infection (determined by investigator).
- •History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation.
- •Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial.
- •Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test.
- •Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period.
- •Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study. Examples include, but are not limited to,hypertension, severe diabetes, or thyroid disease.
- •Alcoholism, smoking (daily ≥ 5 roots) and other bad habits.
- •Known history of neurological or psychiatric disease, including epilepsy or dementia.
研究组 & 干预措施
pyrotinib combined with capecitabine
Experimental
干预措施: pyrotinib combined with capecitabine (Drug)
结局指标
主要结局
The maximum-tolerated dose (MTD) will be defined as the maximum dose level at which no more than one subject out of three experiences has a dose-limiting toxicity (DLT) upon completing one treatment cycle.
时间窗: 21 days
DLT was difined as the cetain AEs which were observed during the first cycle (D1-D21）of treatment.
次要结局
- Cmax, Tmax, T1/2, AUCss and R of pyrotinib and capecitabine in combination(12 months)
- the number of participants with adverse event(12 months)
- preliminary antitumor activity for the regimen, objective response rate(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric CancerHER2 Positive Gastric CancerNCT02378389Jiangsu HengRui Medicine Co., Ltd.28
已完成
2 期
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.HER2 Positive Breast CancerNCT03735966Henan Cancer Hospital75
已完成
1 期
Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast CancerBreast CancerNCT01937689Jiangsu HengRui Medicine Co., Ltd.40
Unknown
3 期
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)HER2 Positive Metastatic Breast CancerNCT03080805Jiangsu HengRui Medicine Co., Ltd.240
进行中（未招募）
3 期
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast CancerHER2 Positive Metastatic Breast CancerNCT02973737Jiangsu HengRui Medicine Co., Ltd.279